Literature DB >> 18045792

A T-cell receptor associated with naturally occurring human tumor immunity.

Bianca D Santomasso1, Wendy K Roberts, Ashby Thomas, Travis Williams, Nathalie E Blachère, Mark E Dudley, Alan N Houghton, Jerome B Posner, Robert B Darnell.   

Abstract

The onconeural antigens appear to serve as tumor rejection antigens in the paraneoplastic neurologic disorders. Here, we used an unbiased peptide binding screen, followed by studies in HLA-A2.1 transgenic mice to identify naturally processed HLA-A2.1 restricted epitopes of the paraneoplastic cerebellar degeneration breast/ovarian cancer antigen cdr2. These mice were used to clone high-avidity cdr2-specific CD8(+) T cells that recognize human tumor cells presenting endogenously loaded MHC class I-cdr2 peptide. T cells with this specificity were detected in the peripheral blood of two HLA-A2.1(+) paraneoplastic cerebellar degeneration patients. We cloned T cell receptor (TCR) alpha and beta genes from cdr2-specific T cells; electroporation of RNA encoding this TCR turned nonreactive donor T cells into efficient killers of human cdr2-expressing tumor cells. Cloned cdr2-specific TCR genes provide a clinically relevant means for immunologic targeting of human gynecologic cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045792      PMCID: PMC2141910          DOI: 10.1073/pnas.0704336104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Observing the invisible: successful tumor immunity in humans.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  Nat Immunol       Date:  2003-03       Impact factor: 25.606

Review 2.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

Review 3.  Paraneoplastic neurological degenerations: keys to tumour immunity.

Authors:  Matthew L Albert; Robert B Darnell
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

4.  Evolution of T cell receptor (TCR) alpha beta heterodimer assembly with the CD3 complex.

Authors:  C Gouaillard; A Huchenq-Champagne; J Arnaud; C L Chen Cl; B Rubin
Journal:  Eur J Immunol       Date:  2001-12       Impact factor: 5.532

5.  Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human.

Authors:  Anne Plonquet; Francisco Garcia-Pons; Eric Fernandez; Caramelle Philippe; Jeanine Marquet; Hélène Rouard; Marie Hélène Delfau-Larue; Konstantinos Kosmatopoulos; François Lemonnier; Jean Pierre Farcet; Romain K Gherardi; Pierre Langlade-Demoyen
Journal:  J Neuroimmunol       Date:  2003-09       Impact factor: 3.478

6.  High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Authors:  Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

7.  High avidity antigen-specific CTL identified by CD8-independent tetramer staining.

Authors:  Ed Man-Lik Choi; Ji-Li Chen; Linda Wooldridge; Mariolina Salio; Anna Lissina; Nikolai Lissin; Ian F Hermans; Jonathan D Silk; Fareed Mirza; Michael J Palmowski; P Rod Dunbar; Bent K Jakobsen; Andy K Sewell; Vincenzo Cerundolo
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

8.  Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice.

Authors:  P A Wentworth; A Vitiello; J Sidney; E Keogh; R W Chesnut; H Grey; A Sette
Journal:  Eur J Immunol       Date:  1996-01       Impact factor: 5.532

Review 9.  Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

10.  Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class I-expressing neurons in vivo.

Authors:  G F Rall; L Mucke; M B Oldstone
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  21 in total

1.  IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.

Authors:  Lidia Yshii; Béatrice Pignolet; Emilie Mauré; Mandy Pierau; Monika Brunner-Weinzierl; Oliver Hartley; Jan Bauer; Roland Liblau
Journal:  JCI Insight       Date:  2019-04-04

2.  T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergy.

Authors:  Nathalie E Blachère; Dana E Orange; Emily C Gantman; Bianca D Santomasso; Graeme C Couture; Teresa Ramirez-Montagut; John Fak; Kevin J O'Donovan; Zhong Ru; Salina Parveen; Mayu O Frank; Michael J Moore; Robert B Darnell
Journal:  JCI Insight       Date:  2017-11-02

3.  MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.

Authors:  Angela L Zarling; Rebecca C Obeng; A Nicole Desch; Joel Pinczewski; Kara L Cummings; Donna H Deacon; Mark Conaway; Craig L Slingluff; Victor H Engelhard
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

4.  RNA regulation in neurologic disease and cancer.

Authors:  Robert B Darnell
Journal:  Cancer Res Treat       Date:  2010-09-30       Impact factor: 4.679

5.  Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.

Authors:  Iñigo Rojas-Marcos; Geraldine Picard; David Chinchón; Ellen Gelpi; Dimitri Psimaras; Bruno Giometto; J Y Delattre; J Honnorat; F Graus
Journal:  Neuro Oncol       Date:  2012-02-20       Impact factor: 12.300

6.  The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells.

Authors:  Kevin J O'Donovan; Jennifer Diedler; Graeme C Couture; John J Fak; Robert B Darnell
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

7.  A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models.

Authors:  Aparna Krishnan; Zhongde Wang; Tumul Srivastava; Ravindra Rawal; Pooja Manchanda; Don J Diamond; Corinna La Rosa
Journal:  Immunol Lett       Date:  2008-08-13       Impact factor: 3.685

8.  Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.

Authors:  Tamson V Moore; Gretchen E Lyons; Natasha Brasic; Jeffrey J Roszkowski; Simon Voelkl; Andreas Mackensen; W Martin Kast; I Caroline Le Poole; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2008-10-03       Impact factor: 6.968

9.  Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.

Authors:  Wendy K Roberts; Ilana J Deluca; Ashby Thomas; John Fak; Travis Williams; Noreen Buckley; Athanasios G Dousmanis; Jerome B Posner; Robert B Darnell
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

10.  T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation.

Authors:  Nathalie E Blachère; Dana E Orange; Bianca D Santomasso; Jessica Doerner; Patricia K Foo; Margaret Herre; John Fak; Sébastien Monette; Emily C Gantman; Mayu O Frank; Robert B Darnell
Journal:  Eur J Immunol       Date:  2014-11       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.